S&P 500
7,551.81
-33.92
-0.45%
Dow
51,461.90
-631.21
-1.21%
Nasdaq
25,978.42
-3.15
-0.01%
NYSE Composite
23,934.15
-194.31
-0.81%
Russell 2000
2,858.81
-11.47
-0.40%
VIX
17.71
+0.51
+2.97%
BBNX · Beta Bionics, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
$22.22
+3.00
(+15.61%)
● At close: September 16 at 4:00:00 PM EDT
DAY'S RANGE
$22.22
$18.66
$22.22
52-WEEK RANGE
$22.22
$8.80
$32.71
What's happening
- BBNX is up 15.61% today, trading at $22.22. — Live quote
- Last quarter's EPS beat estimates: $-0.53 actual vs. $-0.61 estimated (+12.8%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 6
Buy 7
Hold 4
Sell 0
Strong sell 0
Aggregate ratings for 2026-09-01 (17 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
BBNX
-36.89%
vs S&P 500
-47.96%
1-YEAR RETURN
BBNX
-24.02%
vs S&P 500
-38.62%
6-MONTH RETURN
BBNX
+76.91%
3-MONTH RETURN
BBNX
+32.35%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.53
Est. $-0.61
BEAT +12.8%
2026-04-26 (Q1 2026)
$-0.49
Est. $-0.50
BEAT +1.7%
2026-01-26 (Q4 2025)
$-0.29
Est. $-0.42
BEAT +31.6%
2025-10-26 (Q3 2025)
$-0.33
Est. $-0.44
BEAT +25.4%
Valuation Measures & Ratios
Enterprise Value4$708.4M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)6.32
Price / Book72.72
EV4 / Revenue5.95
EV4 / EBITDA—
Profit Margin-61.32%
Operating Margin-69.75%
Return on Equity (ROE8)-26.30%
Return on Assets (ROA9)-23.25%
Avg Volume (3M)1,067,940
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $691.7M | $448.2M | $856.0M | $630.0M | $377.8M |
| P/E | -9.06 | -5.49 | -12.32 | -9.04 | -5.78 |
| Price/Sales | 6.28 | 4.68 | 10.09 | 8.67 | 6.06 |
| Price/Book | 2.70 | 1.65 | 2.90 | 2.09 | 1.20 |
| EV/Revenue | 5.88 | 4.36 | 9.64 | 8.19 | 5.38 |
| ROE | -29.79% | -30.09% | -23.57% | -23.12% | -20.81% |
| ROA | -26.12% | -26.81% | -21.05% | -21.13% | -19.32% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short9,400,691
Change from Prior Settlement+25.43%
% of Float—
Days to Cover (Short Ratio)9.01
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-08-31. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 37.8% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-09-15; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -61.3%. Finnhub fundamentals ↗
- Trailing 52-week price return is -24.0%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on BBNX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $32.0M | $27.6M | $27.3M | $23.2M | $17.6M | $16.7M | $15.0M | $12.9M |
| Gross profit | $18.9M | $16.4M | $15.1M | $12.5M | $9.0M | $8.9M | $8.1M | $7.2M |
| Operating income | -$25.6M | -$24.3M | -$17.0M | -$19.9M | -$18.6M | -$11.0M | -$11.8M | -$9.5M |
| Net income | -$23.4M | -$21.9M | -$14.2M | -$16.9M | -$28.7M | -$9.7M | -$14.5M | -$12.4M |
| EPS (diluted) | $-0.53 | $-0.49 | $-0.33 | $-0.39 | $-0.93 | $-1.46 | $-2.37 | $-2.07 |
| EPS (basic) | $-0.53 | $-0.49 | $-0.33 | $-0.39 | $-0.93 | $-1.46 | $-2.37 | $-2.07 |
| Operating margin | -$80 | -$88 | -$63 | -$86 | -$106 | -$66 | -$78 | -$73 |
| Net margin | -$73 | -$79 | -$52 | -$73 | -$162 | -$58 | -$96 | -$96 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $292.4M | $304.4M | $328.7M | $330.0M | $330.0M | $338.0M | $149.6M | — |
| Total liabilities | $36.0M | $33.2M | $41.1M | $35.3M | $28.3M | $24.3M | $73.6M | — |
| Stockholders' equity | $256.4M | $271.2M | $287.6M | $294.8M | $301.6M | $313.8M | -$245.4M | -$228.8M |
| Total current assets | $231.0M | $248.0M | $267.9M | $270.0M | $286.1M | $261.9M | $132.9M | — |
| Total current liabilities | $26.0M | $23.2M | $30.9M | $25.4M | $19.5M | $16.5M | $21.1M | — |
| Cash & equivalents | $44.3M | $30.2M | $31.6M | $38.5M | $35.1M | $42.5M | $30.4M | $17.5M |
| Marketable securities (current) | $136.2M | $169.3M | $187.5M | $190.2M | $214.6M | $189.0M | $73.1M | — |
| Accounts receivable | $18.1M | $15.8M | $17.1M | $11.5M | $11.4M | $9.1M | $12.0M | — |
| Inventory | $23.9M | $23.7M | $21.7M | $20.4M | $17.3M | $15.7M | $13.3M | — |
| Other current assets | — | — | — | $265.0K | $260.0K | $260.0K | $817.0K | — |
| Marketable securities (non-current) | $44.6M | $39.9M | $45.4M | $45.3M | $31.1M | $64.0M | — | — |
| Property, plant & equipment | $10.7M | $10.2M | $8.6M | $7.4M | $6.5M | $5.5M | $4.8M | — |
| Other non-current assets | $141.0K | $181.0K | $180.0K | $183.0K | $144.0K | $146.0K | $150.0K | — |
| Accounts payable | $5.4M | $2.3M | $5.0M | $4.5M | $3.4M | $3.5M | $2.9M | — |
| Deferred revenue (current) | $1.9M | $1.7M | $1.6M | $1.3M | $1.1M | $949.0K | $939.0K | — |
| Other non-current liabilities | $1.6M | $1.6M | $1.5M | $1.2M | $1.0M | — | — | — |
| Common stock & paid-in capital | $5.0K | $5.0K | $4.0K | $4.0K | $4.0K | $4.0K | $1.0K | — |
| Retained earnings | -$415.2M | -$391.8M | -$369.9M | -$356.5M | -$342.3M | -$325.4M | -$296.7M | — |
| Accumulated other comprehensive income (loss) | -$390.0K | -$96.0K | $403.0K | $354.0K | $149.0K | $240.0K | $65.0K | — |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$14.6M | -$23.8M | -$8.6M | -$8.7M | -$13.6M | -$20.0M | -$14.3M | -$9.6M |
| Investing cash flow | $26.9M | $21.8M | $658.0K | $9.5M | $6.2M | -$179.1M | -$29.7M | $15.2M |
| Financing cash flow | $1.8M | $623.0K | $1.1M | $2.7M | $42.0K | $211.1M | $56.9M | -$1.2M |
| Free cash flow | -$15.7M | -$25.2M | -$10.5M | -$10.0M | -$15.4M | -$20.3M | -$14.8M | -$11.5M |
| Capital expenditures | $1.0M | $1.4M | $1.9M | $1.3M | $1.8M | $333.0K | $561.0K | $1.9M |
| Share-based compensation | $7.0M | $5.4M | $4.3M | $4.5M | $4.8M | $2.8M | $1.6M | $2.0M |
| Change in accounts receivable | $2.3M | -$1.4M | $5.6M | $168.0K | $2.3M | -$2.9M | $4.6M | -$1.5M |
| Change in inventory | $214.0K | $1.8M | $2.2M | $3.3M | $1.7M | $2.6M | $1.2M | $3.9M |
| Change in accounts payable | $2.9M | -$3.3M | $527.0K | $1.1M | $568.0K | -$97.0K | -$61.0K | $106.0K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Revenue | $100.3M | $65.1M | $12.0M |
| Gross profit | $55.5M | $35.9M | $6.3M |
| Operating income | -$71.7M | -$45.3M | -$35.9M |
| Net income | -$73.2M | -$54.8M | -$44.1M |
| EPS (diluted) | $-1.81 | $-8.60 | $-8.31 |
| EPS (basic) | $-1.81 | $-8.60 | $-8.31 |
| Operating margin | -$72 | -$69 | -$299 |
| Net margin | -$73 | -$84 | -$368 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 |
|---|---|---|---|---|
| Total assets | $328.7M | $149.6M | $110.0M | — |
| Total liabilities | $41.1M | $73.6M | $51.4M | — |
| Stockholders' equity | $287.6M | -$245.4M | -$203.1M | -$170.0M |
| Total current assets | $267.9M | $132.9M | $103.6M | — |
| Total current liabilities | $30.9M | $21.1M | $10.6M | — |
| Cash & equivalents | $31.6M | $30.4M | $26.6M | — |
| Marketable securities (current) | $187.5M | $73.1M | $70.2M | — |
| Accounts receivable | $17.1M | $12.0M | $4.4M | — |
| Inventory | $21.7M | $13.3M | $1.2M | — |
| Other current assets | — | $1.1M | $275.0K | — |
| Marketable securities (non-current) | $45.4M | — | — | — |
| Property, plant & equipment | $8.6M | $4.8M | $2.5M | — |
| Other non-current assets | $180.0K | $150.0K | $121.0K | — |
| Accounts payable | $5.0M | $2.9M | $1.2M | — |
| Deferred revenue (current) | $1.6M | $939.0K | $87.0K | — |
| Other non-current liabilities | $1.5M | — | — | — |
| Common stock & paid-in capital | $4.0K | $1.0K | — | — |
| Retained earnings | -$369.9M | -$296.7M | -$229.7M | — |
| Accumulated other comprehensive income (loss) | $403.0K | $65.0K | $137.0K | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Operating cash flow | -$50.9M | -$48.3M | -$32.4M |
| Investing cash flow | -$162.8M | -$3.5M | -$69.7M |
| Financing cash flow | $214.9M | $55.6M | $101.0M |
| Free cash flow | -$56.2M | -$51.7M | -$32.8M |
| Capital expenditures | $5.3M | $3.4M | $402.0K |
| Share-based compensation | $16.4M | $6.4M | $5.7M |
| Change in accounts receivable | $5.2M | $7.6M | $4.5M |
| Change in inventory | $9.9M | $11.4M | $1.2M |
| Change in accounts payable | $2.1M | $1.5M | $716.0K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding BBNX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Set BUSINESSQUANT_API_KEY to enable institutional ownership.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-12-02 to 2026-09-14
Recent transactions
- Insiders have net sold 137,974 shares over the last 182 days, across 0 purchases and 22 sales.
- Most recent: Hopman Mark (Chief Commercial Officer) — Open market sale of 775 shares on 2026-09-14.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)137,974 sh(22 txns)
Net Shares-137,974
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Hopman Mark | Chief Commercial Officer | Open market sale | 2026-09-14 | 775 |
| Saint Sean | President & CEO | Open market sale | 2026-09-03 | 5,641 |
| Russell Steven Jon | Chief Medical Officer | Open market sale | 2026-09-02 | 4,221 |
| Mensinger Mike | Chief Product Officer | Open market sale | 2026-09-02 | 4,375 |
| Feider Stephen | Chief Financial Officer | Open market sale | 2026-09-02 | 6,675 |
| Jones Christy | Reporting person | Open market sale | 2026-06-24 | 1,406 |
| Lezack Adam | Reporting person | Open market sale | 2026-05-22 | 998 |
| MICHEL GERARD J | Reporting person | Grant / award | 2026-05-21 | 16,965 |
| Palasis Maria | Reporting person | Grant / award | 2026-05-21 | 16,965 |
| Dearen Danny L. | Reporting person | Grant / award | 2026-05-21 | 16,965 |
| CARNEY SEAN | Reporting person | Grant / award | 2026-05-21 | 16,965 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-14 | Hopman Mark | Chief Commercial Officer | Open market sale | 775 | $15.52 |
| 2026-09-09 | Hopman Mark | Chief Commercial Officer | Open market sale | 36,870 | $18.46 |
| 2026-09-03 | Saint Sean | President & CEO | Open market sale | 5,641 | $20.08 |
| 2026-09-02 | Hopman Mark | Chief Commercial Officer | Open market sale | 5,327 | $19.11 |
| 2026-09-02 | Russell Steven Jon | Chief Medical Officer | Open market sale | 4,221 | $19.11 |
| 2026-09-02 | Mensinger Mike | Chief Product Officer | Open market sale | 4,375 | $19.11 |
| 2026-09-02 | Feider Stephen | Chief Financial Officer | Open market sale | 6,675 | $19.11 |
| 2026-09-02 | Saint Sean | President & CEO | Open market sale | 16,867 | $19.11 |
| 2026-06-29 | Feider Stephen | Chief Financial Officer | Option exercise | 4,896 | $5.10 |
| 2026-06-29 | Feider Stephen | Chief Financial Officer | Open market sale | 4,896 | $17.03 |
| 2026-06-26 | Feider Stephen | Chief Financial Officer | Option exercise | 4,982 | $5.10 |
| 2026-06-26 | Feider Stephen | Chief Financial Officer | Open market sale | 5,104 | $17.05 |
| 2026-06-24 | Hopman Mark | Chief Commercial Officer | Open market sale | 1,258 | $15.01 |
| 2026-06-24 | Jones Christy | Reporting person | Open market sale | 1,406 | $15.00 |
| 2026-06-04 | Hopman Mark | Chief Commercial Officer | Open market sale | 275 | $12.31 |
| 2026-06-04 | Jones Christy | Reporting person | Open market sale | 2,811 | $14.00 |
| 2026-06-02 | Mensinger Mike | Chief Product Officer | Open market sale | 4,378 | $12.61 |
| 2026-06-02 | Hopman Mark | Chief Commercial Officer | Open market sale | 5,329 | $12.61 |
| 2026-06-02 | Russell Steven Jon | Chief Medical Officer | Open market sale | 4,222 | $12.61 |
| 2026-06-02 | Feider Stephen | Chief Financial Officer | Open market sale | 6,676 | $12.61 |
| 2026-06-02 | Saint Sean | President & CEO | Open market sale | 16,872 | $12.61 |
| 2026-05-22 | Lezack Adam | Reporting person | Open market sale | 998 | $11.21 |
| 2026-05-21 | MICHEL GERARD J | Reporting person | Grant / award | 16,965 | $0.00 |
| 2026-05-21 | Jones Christy | Reporting person | Open market sale | 1,998 | $9.95 |
| 2026-05-21 | Jones Christy | Reporting person | Grant / award | 16,965 | $0.00 |
| 2026-05-21 | Palasis Maria | Reporting person | Grant / award | 16,965 | $0.00 |
| 2026-05-21 | Dearen Danny L. | Reporting person | Grant / award | 16,965 | $0.00 |
| 2026-05-21 | CARNEY SEAN | Reporting person | Grant / award | 16,965 | $0.00 |
| 2026-05-21 | Lezack Adam | Reporting person | Open market sale | 1,000 | $9.95 |
| 2026-05-21 | Lezack Adam | Reporting person | Grant / award | 16,965 | $0.00 |
| 2025-12-04 | Hopman Mark | Chief Commercial Officer | Open market sale | 2,061 | $30.66 |
| 2025-12-02 | Hopman Mark | Chief Commercial Officer | Open market sale | 856 | $29.34 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-09-16 19:58 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-15 | 8-K | 2026-09-14 | View on SEC.gov → |
| 2026-09-15 | 4 | 2026-09-14 | View on SEC.gov → |
| 2026-09-10 | 4 | 2026-09-09 | View on SEC.gov → |
| 2026-09-04 | 4 | 2026-09-03 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-02 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-02 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-02 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-02 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-02 | View on SEC.gov → |
| 2026-07-29 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-29 | 8-K | 2026-07-29 | View on SEC.gov → |
| 2026-06-30 | 4 | 2026-06-26 | View on SEC.gov → |
Recent news
Headlines about BBNX (Beta Bionics, Inc.). Links open the publisher — we don’t host full articles.
-
Latham Advises on Beta Bionics’ US$150 Million Public Offering of Common Stock and Pre-Funded Warrants
Latham & Watkins LLP · 2026-09-16 -
Beta Bionics (BBNX) officer plans 5,300-share sale
Stock Titan · 2026-09-16 -
BETA BIONICS ALERT: Bragar Eagel & Squire, P.C. Announces
GlobeNewswire · 2026-09-16 -
Lawsuit ALERT: Investors who lost money with Beta Bionics, Inc.
openPR.com · 2026-09-16 -
BBNX DEADLINE: Levi & Korsinsky Reminds Beta Bionics, Inc. Investors of Upcoming Securities Class Action Deadline
PR Newswire · 2026-09-16 -
Why is Beta Bionics stock sliding today?
Investing.com · 2026-09-16 -
LuxExperience, Alvotech, Twist Bioscience And Other Big Stocks Moving Higher On Wednesday
Benzinga · 2026-09-16 -
Beta Bionics shares fall as company prices $150M stock offering at $17.25/share
Seeking Alpha · 2026-09-16
No headlines in this category right now — try “All”.